Crescent Share Price

Crescent Share Price

NASDAQ: CBIO | Healthcare
$13.04
-$0.02 (-0.11%) Last updated on 21 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • FAQs

Crescent Stock Performance

Open
$12.74
Prev. Close
$13.06
Circuit Range
N/A
Day Range
$12.74 - $13.22
Year Range
$8.81 - $27.41
Volume
33,501
Average Traded
$13.02

Crescent Share Price Today

As of 21 November 2026, Crescent Biopharma, Inc.'s share price is $13.04. The stock opened at $12.74, compared to its previous close of $13.06. During today's trading session, Crescent Biopharma, Inc.'s share price traded between $12.74 and $13.22, with an average price of $12.98. Over the past 52 weeks, the stock has recorded a high of $27.41 and a low of $8.81. In terms of performance, Crescent Biopharma, Inc.'s share price has declined by 36.54% over the last six months and is down 14.40% on a year-on-year basis.

Crescent Share Price Chart

Line chart of the Crescent price trend over the selected period. The price fell overall, ranging from 12.53 to 13.22, ending at 13.04.
$12.74$13.22
L
Show Current Price
H

Crescent Stock Fundamentals & Key Indicators

Market Cap
N/A
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-3.83
Revenue (TTM)
$10.84B
Return On Equity (TTM)
-58.38%
Profit Margin
-1231.09%
Debt to Equity
0.00
Quarterly Earnings Growth YoY
56.66%

Crescent Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$10.84$1.04$0.00$3.12
Net Profit-$81.06-$21.26-$22.69-$35.13
Net Profit Margin-747.79%-2044.23%N/A-1125.96%
Income ChangeN/A73.77%-6.73%-54.83%

Crescent Annual Profit & Loss

All figures in USD

Particulars20222025
Revenue$102.29$10.84
Net Profit$2.30-$133.45
Net Profit Margin2.25%-1231.09%
Income ChangeN/A-5902.17%

Crescent Balance Sheet

All figures in USD Million

Particulars20252022
Non Current Assets3.6435.1
Current Assets236.6649.65
Total Assets240.2984.75
Non Current Liabilities1.210.29
Current Liabilities36.0712.24
Total Liabilities37.2812.54
Shareholders' Equity203.0172.22

Crescent Cash Flow

Annually

All figures in USD Million

Particulars20252022
Operating-71.5310.68
Investing-72.92-13.81
Financing322.980.0

Corporate Actions

Split
Ex-date: 31 Oct 2023

About Crescent

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Crescent Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$13.43
$13.04
-3.55%
Oct 2026
$14.48
$13.52
-8.37%
Sep 2026
$16.50
$14.76
-18.66%
Aug 2026
$14.59
$18.14
+25.62%
Jul 2026
$17.91
$14.44
-19.62%
Jun 2026
$19.60
$17.96
-12.60%
May 2026
$20.53
$20.55
-7.85%
Apr 2026
$18.83
$22.30
+21.32%
Mar 2026
$11.75
$18.39
+51.19%
Feb 2026
$9.89
$12.16
+27.20%
Jan 2026
$11.51
$9.56
-19.05%
Dec 2025
$14.57
$11.81
-22.51%

Crescent Share Price FAQs